NU 578 UNIT 4 GASTROINTESTINAL PHARMACOLOGY EXAM 2026/2027 | 75
VERIFIED QUESTIONS & ANSWERS | | INSTANT DOWNLOAD .
SECTION 1: ACID-SUPPRESSIVE THERAPY — PROTON PUMP INHIBITORS (Questions 1–10)
1. A patient with chronic GERD has taken omeprazole 20 mg daily for 8 weeks with incomplete relief.
The prescriber considers switching to esomeprazole. Which consideration is MOST relevant to this
choice?
A. Pantoprazole has higher bioavailability and may achieve faster suppression.
B. Esomeprazole, the S-isomer of omeprazole, undergoes less CYP2C19 metabolism, producing higher
systemic exposure.
C. Lansoprazole has a shorter half-life and requires twice-daily dosing.
D. Rabeprazole is acid-labile and requires a prokinetic agent.
Answer: B
Rationale: Esomeprazole is the S-isomer of omeprazole and is metabolized less extensively by CYP2C19
than omeprazole. This results in higher and more consistent systemic exposure, which can improve acid
suppression, particularly in CYP2C19 extensive metabolizers who may not achieve adequate PPI levels
with standard omeprazole dosing. Pantoprazole's bioavailability is actually higher than omeprazole's,
making option A incorrect. Lansoprazole is typically once daily for GERD, and rabeprazole is enteric-
coated and does not require a prokinetic.
2. What is the primary mechanism of action of proton pump inhibitors (PPIs)?
A. Reversible competitive blockade of histamine at H₂ receptors.
B. Irreversible inhibition of the H⁺/K⁺-ATPase pump on the luminal membrane of gastric parietal cells.
C. Neutralization of gastric acid by a weak base.
D. Blockade of muscarinic M₃ receptors on parietal cells.
Answer: B
Rationale: PPIs are prodrugs that are activated in the acidic environment of the parietal cell canaliculus.
The active form covalently binds to and irreversibly inhibits the H⁺/K⁺-ATPase (the proton pump), the
final common pathway for gastric acid secretion. Because the inhibition is irreversible, acid suppression
persists long after the drug has cleared from plasma, until new pump molecules are synthesized. H₂
receptor antagonists act reversibly at histamine receptors, antacids neutralize existing acid, and
anticholinergics block muscarinic receptors.
,3. Why do PPIs produce prolonged acid suppression (up to 48 hours or more) despite a short plasma
half-life of approximately 1–2 hours?
A. They are stored in adipose tissue and released slowly.
B. They irreversibly inactivate the proton pump, so recovery requires synthesis of new pump protein.
C. They undergo enterohepatic recirculation, prolonging their presence in the gut.
D. They are converted to active metabolites that have a very long half-life.
Answer: B
Rationale: The duration of action of PPIs is determined not by their plasma half-life but by the turnover
of the proton pump. Because the drug binds covalently and irreversibly to the H⁺/K⁺-ATPase, acid
secretion remains suppressed until new pump molecules are synthesized and inserted into the parietal
cell membrane. This explains why once-daily dosing can maintain effective acid control despite rapid
plasma clearance. The other options do not account for the established pharmacodynamics of PPIs.
4. A patient on long-term omeprazole therapy is at increased risk for which of the following adverse
effects?
A. Hyperkalemia and hypertension.
B. Clostridioides difficile infection and hypomagnesemia.
C. Tardive dyskinesia and hyperprolactinemia.
D. Nephrogenic diabetes insipidus and metabolic acidosis.
Answer: B
Rationale: Prolonged PPI use is associated with an increased risk of enteric infections, including C.
difficile, because the reduction in gastric acid removes a key barrier to ingested pathogens. PPIs also
impair intestinal magnesium absorption, leading to hypomagnesemia in some patients, particularly with
long-term use. Hyperkalemia is not a typical PPI effect (it is more associated with potassium-sparing
diuretics), tardive dyskinesia is a dopamine antagonist effect, and nephrogenic diabetes insipidus is
unrelated to PPI therapy.
5. Which of the following is a clinically important drug interaction with omeprazole?
A. Omeprazole induces CYP3A4, reducing the efficacy of oral contraceptives.
B. Omeprazole inhibits CYP2C19, increasing plasma levels of clopidogrel's active metabolite.
C. Omeprazole inhibits CYP2C19, potentially reducing the activation of clopidogrel and decreasing its
antiplatelet effect.
D. Omeprazole chelates calcium, reducing the absorption of calcium supplements.
Answer: C
Rationale: Clopidogrel is a prodrug that requires activation by CYP2C19. Omeprazole (and
esomeprazole) inhibit CYP2C19, which can reduce the conversion of clopidogrel to its active metabolite,
potentially diminishing its antiplatelet efficacy. This interaction has led to recommendations to avoid
concomitant use of omeprazole or esomeprazole with clopidogrel when possible, or to use a PPI with
, less CYP2C19 inhibition (e.g., pantoprazole). Omeprazole does not induce CYP3A4, and it does not
chelate calcium in a clinically significant manner.
6. A patient is prescribed pantoprazole. Which statement about its bioavailability relative to
omeprazole is correct?
A. Pantoprazole has lower bioavailability than omeprazole.
B. Pantoprazole has higher bioavailability (approximately 77%) than omeprazole (approximately 30–
40%).
C. Both drugs have identical bioavailability.
D. Pantoprazole is not bioavailable orally and must be given intravenously.
Answer: B
Rationale: Pantoprazole has a higher oral bioavailability (approximately 77%) compared with
omeprazole (approximately 30–40%). Despite this pharmacokinetic difference, the clinical significance is
limited because PPIs are dosed to achieve maximal acid suppression, and the higher bioavailability of
pantoprazole does not necessarily translate into superior clinical outcomes in all patients. The other
statements are factually incorrect.
7. Which PPI formulation is available as an immediate-release capsule that can be opened and
sprinkled on food for patients with dysphagia?
A. Omeprazole delayed-release capsules.
B. Esomeprazole delayed-release capsules.
C. Lansoprazole orally disintegrating tablets and capsules that can be opened.
D. Rabeprazole enteric-coated tablets.
Answer: C
Rationale: Lansoprazole is available as orally disintegrating tablets and as capsules containing enteric-
coated granules that can be opened and sprinkled on applesauce or other soft food for patients who
have difficulty swallowing. This is a practical consideration in patients with dysphagia or those with
feeding tubes. The other PPIs are formulated as delayed-release or enteric-coated products that should
generally not be crushed or chewed.
8. A patient with Zollinger-Ellison syndrome requires high-dose PPI therapy. Which principle guides
dosing in this condition?
A. PPIs should be given on an empty stomach once weekly.
B. High-dose PPIs are needed to suppress the markedly increased gastrin-driven acid secretion, often
requiring multiple daily doses.
C. H₂ receptor antagonists are preferred over PPIs for Zollinger-Ellison syndrome.
D. Antacids are the first-line therapy for Zollinger-Ellison syndrome.
VERIFIED QUESTIONS & ANSWERS | | INSTANT DOWNLOAD .
SECTION 1: ACID-SUPPRESSIVE THERAPY — PROTON PUMP INHIBITORS (Questions 1–10)
1. A patient with chronic GERD has taken omeprazole 20 mg daily for 8 weeks with incomplete relief.
The prescriber considers switching to esomeprazole. Which consideration is MOST relevant to this
choice?
A. Pantoprazole has higher bioavailability and may achieve faster suppression.
B. Esomeprazole, the S-isomer of omeprazole, undergoes less CYP2C19 metabolism, producing higher
systemic exposure.
C. Lansoprazole has a shorter half-life and requires twice-daily dosing.
D. Rabeprazole is acid-labile and requires a prokinetic agent.
Answer: B
Rationale: Esomeprazole is the S-isomer of omeprazole and is metabolized less extensively by CYP2C19
than omeprazole. This results in higher and more consistent systemic exposure, which can improve acid
suppression, particularly in CYP2C19 extensive metabolizers who may not achieve adequate PPI levels
with standard omeprazole dosing. Pantoprazole's bioavailability is actually higher than omeprazole's,
making option A incorrect. Lansoprazole is typically once daily for GERD, and rabeprazole is enteric-
coated and does not require a prokinetic.
2. What is the primary mechanism of action of proton pump inhibitors (PPIs)?
A. Reversible competitive blockade of histamine at H₂ receptors.
B. Irreversible inhibition of the H⁺/K⁺-ATPase pump on the luminal membrane of gastric parietal cells.
C. Neutralization of gastric acid by a weak base.
D. Blockade of muscarinic M₃ receptors on parietal cells.
Answer: B
Rationale: PPIs are prodrugs that are activated in the acidic environment of the parietal cell canaliculus.
The active form covalently binds to and irreversibly inhibits the H⁺/K⁺-ATPase (the proton pump), the
final common pathway for gastric acid secretion. Because the inhibition is irreversible, acid suppression
persists long after the drug has cleared from plasma, until new pump molecules are synthesized. H₂
receptor antagonists act reversibly at histamine receptors, antacids neutralize existing acid, and
anticholinergics block muscarinic receptors.
,3. Why do PPIs produce prolonged acid suppression (up to 48 hours or more) despite a short plasma
half-life of approximately 1–2 hours?
A. They are stored in adipose tissue and released slowly.
B. They irreversibly inactivate the proton pump, so recovery requires synthesis of new pump protein.
C. They undergo enterohepatic recirculation, prolonging their presence in the gut.
D. They are converted to active metabolites that have a very long half-life.
Answer: B
Rationale: The duration of action of PPIs is determined not by their plasma half-life but by the turnover
of the proton pump. Because the drug binds covalently and irreversibly to the H⁺/K⁺-ATPase, acid
secretion remains suppressed until new pump molecules are synthesized and inserted into the parietal
cell membrane. This explains why once-daily dosing can maintain effective acid control despite rapid
plasma clearance. The other options do not account for the established pharmacodynamics of PPIs.
4. A patient on long-term omeprazole therapy is at increased risk for which of the following adverse
effects?
A. Hyperkalemia and hypertension.
B. Clostridioides difficile infection and hypomagnesemia.
C. Tardive dyskinesia and hyperprolactinemia.
D. Nephrogenic diabetes insipidus and metabolic acidosis.
Answer: B
Rationale: Prolonged PPI use is associated with an increased risk of enteric infections, including C.
difficile, because the reduction in gastric acid removes a key barrier to ingested pathogens. PPIs also
impair intestinal magnesium absorption, leading to hypomagnesemia in some patients, particularly with
long-term use. Hyperkalemia is not a typical PPI effect (it is more associated with potassium-sparing
diuretics), tardive dyskinesia is a dopamine antagonist effect, and nephrogenic diabetes insipidus is
unrelated to PPI therapy.
5. Which of the following is a clinically important drug interaction with omeprazole?
A. Omeprazole induces CYP3A4, reducing the efficacy of oral contraceptives.
B. Omeprazole inhibits CYP2C19, increasing plasma levels of clopidogrel's active metabolite.
C. Omeprazole inhibits CYP2C19, potentially reducing the activation of clopidogrel and decreasing its
antiplatelet effect.
D. Omeprazole chelates calcium, reducing the absorption of calcium supplements.
Answer: C
Rationale: Clopidogrel is a prodrug that requires activation by CYP2C19. Omeprazole (and
esomeprazole) inhibit CYP2C19, which can reduce the conversion of clopidogrel to its active metabolite,
potentially diminishing its antiplatelet efficacy. This interaction has led to recommendations to avoid
concomitant use of omeprazole or esomeprazole with clopidogrel when possible, or to use a PPI with
, less CYP2C19 inhibition (e.g., pantoprazole). Omeprazole does not induce CYP3A4, and it does not
chelate calcium in a clinically significant manner.
6. A patient is prescribed pantoprazole. Which statement about its bioavailability relative to
omeprazole is correct?
A. Pantoprazole has lower bioavailability than omeprazole.
B. Pantoprazole has higher bioavailability (approximately 77%) than omeprazole (approximately 30–
40%).
C. Both drugs have identical bioavailability.
D. Pantoprazole is not bioavailable orally and must be given intravenously.
Answer: B
Rationale: Pantoprazole has a higher oral bioavailability (approximately 77%) compared with
omeprazole (approximately 30–40%). Despite this pharmacokinetic difference, the clinical significance is
limited because PPIs are dosed to achieve maximal acid suppression, and the higher bioavailability of
pantoprazole does not necessarily translate into superior clinical outcomes in all patients. The other
statements are factually incorrect.
7. Which PPI formulation is available as an immediate-release capsule that can be opened and
sprinkled on food for patients with dysphagia?
A. Omeprazole delayed-release capsules.
B. Esomeprazole delayed-release capsules.
C. Lansoprazole orally disintegrating tablets and capsules that can be opened.
D. Rabeprazole enteric-coated tablets.
Answer: C
Rationale: Lansoprazole is available as orally disintegrating tablets and as capsules containing enteric-
coated granules that can be opened and sprinkled on applesauce or other soft food for patients who
have difficulty swallowing. This is a practical consideration in patients with dysphagia or those with
feeding tubes. The other PPIs are formulated as delayed-release or enteric-coated products that should
generally not be crushed or chewed.
8. A patient with Zollinger-Ellison syndrome requires high-dose PPI therapy. Which principle guides
dosing in this condition?
A. PPIs should be given on an empty stomach once weekly.
B. High-dose PPIs are needed to suppress the markedly increased gastrin-driven acid secretion, often
requiring multiple daily doses.
C. H₂ receptor antagonists are preferred over PPIs for Zollinger-Ellison syndrome.
D. Antacids are the first-line therapy for Zollinger-Ellison syndrome.
